Lee's Pharmaceutical Holdings (FRA:L1PA) Short Interest


FRA:L1PA Lee's Pharmaceutical Holdings Ltd FRA:L1PA
74 GF Score
Price €0.11
GF Value €0.17
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:L1PA vs ZTS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lee's Pharmaceutical Holdings Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Short Interest falls into.


FRA:L1PA
74GF Score
Lee's Pharmaceutical Holdings Ltd FRA:L1PA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of €0.11 is trading 37.1% below its estimated GF Value™ of €0.17.

Key valuation signals for FRA:L1PA:

  • Short Interest:
  • GF Value™: €0.17 vs. price of €0.11 (37.1% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for FRA:L1PA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.17
GF Value